Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9), a life sciences company focused on artisanal functional and psychedelic mushrooms, recently found a new potential functional property and health benefit for its AME-1 following its early research.
The National Research Council of Canada (NRC) has generated preliminary evidence showing that AME-1 extract can decrease human connective-tissue mast cell activation. Mast cells are inflammatory cells that can be found in the skin, gut, brain, and lungs. These cells emit proinflammatory mediators including histamine and cytokines when triggered, contributing to skin inflammatory illnesses such atopic dermatitis and urticaria, often known as hives.
“The first set of preliminary evidence in this investigative study of AME-1 reveals the discovery of a novel health and wellness benefit, as well as a new functional property,” said Brian Tancowny, Scientific Advisor to Psyched. “We are further investigating the potential of AME-1 to inhibit human mast cell activation and explore the potential of therapies to treat common skin conditions. It is very inspiring to have found an additional functional immune property of AME-1, and further work is being done to investigate this possibility, as well as potential neuroprotective properties of AME-1.”
Pre-treating human mast cells with AME-1 extract prevented their activation and partially blocked the release of proinflammatory mediators, according to the findings. This first evidence reveals that AME-1 may have a critical nutritional systematic and functional characteristic, with study into the mechanisms of inhibition continuing.
